DBVT (DBV Technologies) Cyclically Adjusted PS Ratio: (As of Jul. 09, 2026)


DBVT DBV Technologies SA DBVT
31 GF Score
Price $16.08
! 1 Warning Sign
View Full Analysis

What is DBV Technologies Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


DBV Technologies  (NAS:DBVT) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


DBV Technologies Cyclically Adjusted PS Ratio Related Terms


DBV Technologies Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for DBV Technologies's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DBV Technologies Cyclically Adjusted PS Ratio Chart

DBV Technologies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

DBV Technologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

DBVT vs VRTX, REGN, ALNY: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, DBV Technologies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DBV Technologies Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DBV Technologies's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where DBV Technologies's Cyclically Adjusted PS Ratio falls into.


DBVT
31GF Score
DBV Technologies SA DBVT
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DBV Technologies Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

DBV Technologies's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, DBV Technologies's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/122.4300*122.4300
=0.000

Current CPI (Mar. 2026) = 122.4300.

DBV Technologies Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201312 0.000 99.800 0.000
201406 0.000 100.180 0.000
201412 0.000 99.860 0.000
201506 0.000 100.440 0.000
201512 0.000 100.040 0.000
201606 0.000 100.630 0.000
201612 0.000 100.650 0.000
201706 0.000 101.320 0.000
201712 0.000 101.850 0.000
201806 0.000 103.370 0.000
201809 0.000 103.560 0.000
201812 0.000 103.470 0.000
201906 0.000 104.580 0.000
201909 0.000 104.500 0.000
201912 0.000 104.980 0.000
202003 0.000 104.590 0.000
202006 0.000 104.790 0.000
202009 0.000 104.550 0.000
202012 0.000 104.960 0.000
202103 0.000 105.750 0.000
202106 0.000 106.340 0.000
202109 0.000 106.810 0.000
202112 0.000 107.850 0.000
202203 0.000 110.490 0.000
202206 0.000 112.550 0.000
202209 0.000 112.740 0.000
202212 0.000 114.160 0.000
202303 0.000 116.790 0.000
202306 0.000 117.650 0.000
202309 0.000 118.260 0.000
202312 0.000 118.390 0.000
202403 0.000 119.470 0.000
202406 0.000 120.200 0.000
202409 0.000 119.560 0.000
202412 0.000 119.950 0.000
202503 0.000 120.380 0.000
202506 0.000 121.360 0.000
202509 0.000 120.950 0.000
202512 0.000 120.900 0.000
202603 0.000 122.430 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


DBV Technologies Business Description

Address 107 Avenue de la Republique, Batiment IRO, Chatillon, Paris, FRA, 92320
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
31GF Score

Get the complete analysis for DBVT

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.08
Price